Pro Medicus (PME.AX) Stock Price
Pro Medicus Price
Revenue has compounded at 17.3% per year over the past 19 years to 261.69 M AUD. Earnings per share have grown at 20.8% per year over the last 19 years. Pro Medicus's net margin stands at 101.4%, up from 47.6% several years earlier. Pro Medicus currently offers a dividend yield of about 0.56%. The payout ratio is around 73% of earnings. The dividend has grown at 21.6% per year over the past 19 years. Analysts set a median price target of 244.80 AUD, implying 53.7% above the current price. Of 17 analysts, 11 rate the stock a buy — an overall Buy consensus.
Pro Medicus stock price
Pro Medicus business model & stock analysis
Frequently asked questions about Pro Medicus
The business model of Pro Medicus Ltd revolves around providing advanced healthcare imaging software solutions. The company specializes in developing and delivering a comprehensive range of radiology solutions that enhance workflow efficiency and improve patient care. Pro Medicus offers cutting-edge products like Visage AI, Visage 7, and Visage RIS, which allow healthcare professionals to efficiently manage and analyze medical images. By combining innovative technology with a customer-centric approach, Pro Medicus helps healthcare providers worldwide optimize their imaging operations and deliver accurate diagnoses. With its focus on developing state-of-the-art software solutions, Pro Medicus positions itself as a leader in the medical imaging industry.
Pro Medicus Ltd is primarily active in the healthcare industry.
The main competitors of Pro Medicus Ltd in the market include other medical imaging companies such as Carestream Health, Change Healthcare, and Sectra AB. These companies also specialize in providing medical imaging solutions and technology to healthcare providers and are prominent players in the industry. Pro Medicus Ltd competes with them in terms of product offerings, innovation, customer base, and market share.
Pro Medicus Ltd is a renowned healthcare imaging and information technology provider. Established in 1983, the company has a rich history of pioneering innovative solutions in the medical imaging industry. With a strong focus on radiology, Pro Medicus has developed advanced imaging software that improves efficiency and enhances patient care. The company's success is attributed to its commitment to research and development, resulting in cutting-edge technologies and multiple industry awards. Pro Medicus operates globally, serving prominent healthcare institutions and professionals. With its profound expertise and dedication to advancing medical imaging technology, Pro Medicus Ltd continues to lead the industry in providing innovative solutions for the healthcare sector.
Some significant milestones achieved by Pro Medicus Ltd include the successful expansion into major global markets, such as the United States and Europe, further solidifying its position as a leading provider of healthcare imaging solutions. The company has also experienced continuous revenue growth, achieving record-breaking financial results year after year. Pro Medicus Ltd has consistently developed and released innovative software solutions, enhancing efficiency and productivity for healthcare professionals. Additionally, the company has formed strategic partnerships with top-tier healthcare organizations, further establishing its reputation as a trusted industry leader. These accomplishments have propelled Pro Medicus Ltd's growth and success in the competitive healthcare technology sector.
Pro Medicus Ltd primarily operates in Australia and the United States.
Pro Medicus Ltd is a leading healthcare IT solutions provider with a strong commitment to excellence and innovation. The company's core values revolve around delivering exceptional products and services that empower healthcare professionals to enhance patient care and outcomes. Pro Medicus emphasizes a customer-centric approach and strives to provide customized solutions tailored to meet the unique needs of its clients. With a clear focus on technological advancements and high-quality imaging software, Pro Medicus constantly pushes the boundaries in the healthcare industry. By fostering a culture of collaboration and continuous improvement, Pro Medicus Ltd is dedicated to transforming the way medical images are managed and shared worldwide.
Analysts currently set an average price target of 226.59 AUD for the Pro Medicus stock (median: 244.80 AUD), implying +44.0 % versus the latest price. The consensus is based on 17 analyst ratings.
17 analysts currently rate the Pro Medicus stock: 13 recommend buying, 4 holding and 0 selling.
Converted at the current exchange rate, the Pro Medicus share trades at 98.90 EUR (159.25 AUD).
The Pro Medicus share (PME.AX) is listed on 3 stock exchanges, including: ASX (PME.AX), Frankfurt (PMC.F).
Pro Medicus Ltd is a global company specializing in providing advanced IT solutions for the healthcare industry. They offer innovative information and image management solutions that are used by leading healthcare organizations worldwide. Their main divisions include Picture Archiving and Communication Systems (PACS), Radiology Information Systems (RIS), and Telemedicine. Their PACS solutions allow hospitals and healthcare organizations to store, manage, and share digital images from medical diagnostic devices such as CT, MRI, and X-ray machines. These solutions are scalable and provide high-quality image quality for radiologists and other specialists to make informed diagnoses. Their RIS is an integrated solution designed specifically for radiology departments and practices, providing complete patient and order management, as well as integrated workflow tools to improve the efficiency and accuracy of diagnosing and evaluating medical imaging data. Their telemedicine solutions enable radiology professionals to edit and share medical images remotely over the internet, particularly beneficial in facilities with limited resources or for quick access to medical images in emergency diagnoses. In addition, Pro Medicus Ltd also offers specialized solutions for clinical decision support, automated medical image analysis, and patient management. Their clinical decision support provides assistance to medical professionals in diagnosis and treatment monitoring, while the automated analysis of medical image data allows for the quick processing of large amounts of data, producing results that can be utilized by professionals for diagnostic purposes. Their patient management solutions provide comprehensive capture and management of health data that can be used by doctors and other professionals to develop better treatment options for their patients. Pro Medicus Ltd is a global company with a strong focus on research and development. They have partnerships with leading healthcare organizations worldwide and possess a strong portfolio of intellectual property. Their business model is based on the sale of products and services specifically designed for the needs of the healthcare industry. The company emphasizes innovation, customer satisfaction, and delivering high-quality solutions that are scalable and flexible for various users. Overall, Pro Medicus Ltd is an innovative market leader in the field of medical IT solutions. They are globally recognized for their products and services and are expected to continue playing a significant role in the healthcare industry.
The revenue of Pro Medicus is 261.69 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Pro Medicus is 265.34 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Pro Medicus is currently 62.80. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pro Medicus stock.
The price-to-sales ratio (P/S) of Pro Medicus is currently 63.68. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pro Medicus stock.
The Eulerpool Quality Score for Pro Medicus is 8/10.
The ISIN of Pro Medicus is AU000000PME8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Pro Medicus is 591723. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Pro Medicus is PME.AX. The ticker symbol is used to trade Pro Medicus shares on the stock exchange.
Pro Medicus stock
Pro Medicus Peer Group
Pro Medicus Ticker
Pro Medicus FIGI
All fundamentals and in-depth analysis of Pro Medicus
Our stock analysis for Pro Medicus stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pro Medicus. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.